Drugs that contain Bendamustine Hydrochloride

1. Drug name - BELRAPZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

Treatment: For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

2. Drug name - BENDEKA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

3. Drug name - TREANDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445524 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

CN105693620A CEPHALON Bendamustine Hydrochloride Solid Form
Sep, 2018

(4 years ago)

CN101980698A CEPHALON Novel Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

CN103550159B CEPHALON Bendamustine Hydrochloride In Solid Form
Mar, 2029

(6 years from now)

CN103550159A CEPHALON Solid Form Hydrochloric Bendamustine
Mar, 2029

(6 years from now)

CN101980698B CEPHALON Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

EP2271315A2 CEPHALON Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

EP2271315B1 CEPHALON Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895756 CEPHALON Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US8609863 CEPHALON Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US8791270 CEPHALON Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US8895756

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Jul, 2026

(3 years from now)

US8609863

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Jul, 2026

(3 years from now)

US8791270

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Jul, 2026

(3 years from now)

US8883836 CEPHALON Solid forms of bendamustine hydrochloride Mar, 2029

(6 years from now)

US9533955 CEPHALON Solid forms of bendamustine hydrochloride Mar, 2029

(6 years from now)

US8669279 CEPHALON Solid forms of bendamustine hydrochloride Mar, 2029

(6 years from now)

US8344006 CEPHALON Liquid formulations of bendamustine Sep, 2029

(6 years from now)

US8883836

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride Sep, 2029

(6 years from now)

US8445524

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride Sep, 2029

(6 years from now)

US8669279

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride Sep, 2029

(6 years from now)

US8344006

(Pediatric)

CEPHALON Liquid formulations of bendamustine Mar, 2030

(7 years from now)

US8436190 CEPHALON Bendamustine pharmaceutical compositions Oct, 2030

(8 years from now)

US8436190

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Apr, 2031

(8 years from now)

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; for use in the treatment of patients with chronic lymphocytic leukemia (cll)

Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
25MG/VIAL POWDER;IV (INFUSION) Prescription
100MG/VIAL POWDER;IV (INFUSION) Prescription
45MG/0.5ML (90MG/ML) SOLUTION;IV (INFUSION) Discontinued
180MG/2ML (90MG/ML) SOLUTION;IV (INFUSION) Discontinued

availability in other generic markets.

Click on the highlighted region to filter.